BioArctic: Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease published in the New England Journal of Medicine

STOCKHOLM, Nov. 30, 2022 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory

Related Keywords

Japan , Tokyo , United Kingdom , Uppsala , Uppsala Lan , Sweden , San Diego , California , United States , Toronto , Ontario , Canada , Mannheim , Baden Wüberg , Germany , Wellington , New Zealand General , New Zealand , Stockholm , Singapore , National University Of Singapore , Singapore General , University Of Southern California , Phoenix , Arizona , Heidelberg , France , Swedish , Sharon Cohen , Larisa Reyderman , Sadao Katayama , David Li , Takeshi Iwatsubo , Paul Aisen , Michelle Gee , David Watson , Gunilla Osswald , Lynnd Kramer , Oskar Bosson , Lutz Froelich , Marwan Sabbagh , Christopher Chen , Bruno Vellas , Randallj Bateman , Shobha Dhadda , Paul Sabatier , Michio Kanekiyo , Michael Irizarry , Uppsala University , Vp Communications , Department Of Neuropathology , School Of Medicine , Toulouse Gerontopole University Hospital , Barrow Neurological Institute , National Institute On , Nasdaq , Alzheimer Therapeutic Research Institute , Toronto Memory Program , Japan Pharmaceuticals , Cognition Center , Alzheimer Disease Research Unit , Yale School Of Medicine , National Center , Alzheimer Research , Treatment Center , National Institutes Of Health , Yong Loo Lin School Of Medicine , Drug Administration , Department Of Pharmacology , Washington University School Of Medicine , Central Institute Of Mental Health , University Of Tokyo , Alzheimer Network Trials Unit , Devices Agency , University Of Heidelberg , Alzheimer Clinical Trial Consortium , New England Journal , Early Alzheimer , Disease Research Unit , Yale School , New Haven , Therapeutic Research Institute , Southern California , Washington University School , Yong Loo Lin School , National University , Medical Faculty Mannheim , Central Institute , Mental Health , Katayama Medical Clinic , Graduate School , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited Alzheimer , Biologics License Application , Accelerated Approval Pathway , Prescription Drug User Fee Act , Approval Pathway , Medical Devices Agency , Commercialization Agreement , Nasdaq Stockholm Mid Cap , Bioarctic , Bull , Results , Lecanemab , Hase , Confirmatory , Clarity , Study , Early , Lzheimer , Disease , Published , England , Journal , Medicine ,